Newleos Wins NIDA Grant for NTX-2001 Addiction Studies

The first study supported by Newleos Therapeutics' new cocaine-use-disorder grant addresses drug interactions. An efficacy study follows, giving the Boston biotech a sequence of clinical questions to work through before the promise of its molecule can become evidence for that disorder.

On November 3, 2026, Newleos announced a five-year, milestone-based NIDA grant of up to $15.5M for NTX-2001, an investigational drug targeting trace amine-associated receptor 1, or TAAR1. The National Institute on Drug Abuse, part of the National Institutes of Health, is supporting development in cocaine use disorder through a Phase 1 drug-drug interaction study and a subsequent Phase 2 efficacy study.

Newleos also reported FDA Fast Track designation for NTX-2001 in alcohol use disorder, where a Phase 1b study is already underway. Together, the developments show how a single molecule can acquire different financing arrangements and regulatory conversations as a company investigates its use across related conditions.

A federal award with a specific assignment

The $15.5M figure is the grant's maximum announced value, distributed over a five-year, milestone-based program. Newleos describes the award as its first federal grant and identifies NIH award number 1UG3DA066264-01. Readers tracking financing should retain those conditions wherever the amount travels.

A defined study sequence makes the announcement more useful than a headline tally. The interaction work precedes the efficacy study, tying federal backing to the construction of a clinical evidence package. There is no disclosed basis for treating the entire ceiling as cash already received, and the company has not published a complete milestone or drawdown schedule in the announcement.

That structure sits alongside a different kind of backing. Newleos launched publicly in February 2025 with a $93.5M Series A, led by Goldman Sachs Alternatives with Novo Holdings A/S, Longwood Fund, DCVC Bio and Arkin Bio Capital participating. The earlier financing supported a portfolio licensed from Roche; NIDA's latest award directs support toward a particular program and indication. Adding those two headline numbers would blur the distinction between an equity financing and a conditional research commitment.

For an operator, the practical change is a more defined set of studies to organize around NTX-2001. The announcement provides neither a new valuation nor commercial-sales evidence, so the useful milestones remain the research itself and the information it can produce.

One molecule, two clinical development paths

NTX-2001 is a selective partial agonist of TAAR1, a receptor involved in brain circuits associated with dopamine signaling and reward. Newleos' current pipeline description explains the biological rationale for investigating that mechanism in substance use disorders. The rationale supports testing a hypothesis; whether the drug benefits people with either disorder remains a clinical question.

The alcohol program has already reached participants. In its April 29 study announcement, Newleos described a randomized, double-blind, placebo-controlled Phase 1b trial conducted with Yale School of Medicine. The study examines drinking behavior using an alcohol drinking paradigm, alongside safety, tolerability and pharmacokinetics. That setting gives the company a controlled way to investigate the compound's effects before making broader claims about treatment.

Newleos' earlier NTX-2001 experience also requires careful reading. The April release described eight previous trials involving approximately 645 participants receiving either the compound or placebo. Those participants should not all be counted as recipients of the active drug, nor should experience in other study populations be treated as demonstrated efficacy in addiction.

In the November announcement, co-founder and CMO Federico Bolognani said topline alcohol-study data are expected in the first half of 2027. That is the company's prospective timetable. The cocaine program has its own interaction and efficacy studies to carry forward under the grant.

What Fast Track changes for the alcohol program

The FDA designation reported by Newleos applies specifically to alcohol use disorder. The agency's Fast Track guidance describes a process intended to facilitate development and expedite review for drugs addressing serious conditions and unmet medical needs. Benefits can include more frequent communication with the agency and rolling review of an application.

Accelerated Approval and Priority Review have additional eligibility criteria. The designation therefore gives the development team opportunities to discuss its evidence and plans with the FDA while the clinical work continues. Commercial authorization remains a separate decision requiring the relevant evidence and review.

Keeping the indication attached to the designation is essential. A reader following the NIDA grant could otherwise assume that the cocaine-use-disorder program received the same regulatory status. The company disclosed federal grant support for cocaine-use-disorder development and Fast Track for alcohol-use-disorder development, creating two distinct records around NTX-2001.

Newleos' expanded-access policy makes the present stage tangible: its investigational products have no commercial approval, and the company currently limits access to clinical trials. That is where the evidence supporting future decisions must be generated, with study participation and data collection carrying their own responsibilities.

The team carrying the Roche pipeline forward

Newleos was co-founded by Longwood Fund, Federico Bolognani and William Martin. Its current leadership page lists Timothy Noyes as CEO and Federico Bolognani as co-founder and CMO. Those current roles matter when reading launch-era coverage, which identified David Donabedian as founding CEO.

The broader company is pursuing several neuropsychiatric mechanisms, including GABA-A gamma-1, V1a and GABA-A alpha-5 programs alongside TAAR1. A portfolio creates choices about where to deploy management attention, clinical capabilities and capital. A grant dedicated to NTX-2001 in cocaine use disorder gives one part of that portfolio a specific externally supported assignment.

For biotechnology investors and development teams, the next useful information will come at that level of detail: what each study establishes, which population it studies and how the findings inform the next protocol. As the alcohol study moves toward its expected 2027 readout, Federico Bolognani's team also has the cocaine program's interaction work and subsequent efficacy study to build into the same company's clinical calendar.